EBC is a network of key players in the “Brain Area”, with a membership encompassing scientific societies, patient organisations, professional societies and industry partners.
4 06-2022

Value of Treatment Symposium on Mental Health | 30th European Congress of Psychiatry

2022-04-29T13:14:23+00:0004-06-2022|

Recent studies underscore the severity of the mental health challenges children and adolescents face that can lead to high disability. There are numerous unmet needs along the care pathways, although effective early detection and interventions exist. Navigating the mental health services system is often complex for families, due to fragmented or disrupted services. The Value [...]

1 05-2022

Value of Treatment (VOT) case study on phenylketonuria (PKU) | EPNS Congress 2022

2022-03-30T12:45:15+00:0001-05-2022|

  The Value of Treatment for Brain Disorders (VOT) is a health economics and outcomes research project coordinated by the European Brain Council (EBC). According to the World Health Organization, disorders of the brain affect up to one in three people worldwide.  A second round (VOT2) on new therapeutic areas was launched in 2019, focusing on The Value of [...]

30 04-2022

Value of Treatment (VOT) case study on ataxia | EPNS Congress 2022

2022-03-30T12:39:43+00:0030-04-2022|

  The Value of Treatment for Brain Disorders (VOT) is a health economics and outcomes research project coordinated by the European Brain Council (EBC). According to the World Health Organization, disorders of the brain affect up to one in three people worldwide.  A second round (VOT2) on new therapeutic areas was launched in 2019, focusing on The Value [...]

10 10-2021

EBC raises awareness on World Mental Health Day

2021-10-15T07:16:47+00:0010-10-2021|News|

EBC is happy to support and recognise World Mental Health Day, which takes place annually on 10 October. The overall objective of World Mental Health Day is to raise awareness of mental health issues around the world and to mobilise efforts in support of mental health. This year's theme is ‘Mental Health in an Unequal [...]

28 06-2021

VOT2 Case Studies on Rare Diseases & Mental Disorders present findings at Synthesis Meeting on 8 June 2021

2021-08-30T14:11:31+00:0028-06-2021|News|

On 8 June 2021, EBC hosted a virtual Synthesis Meeting for the Value of Treatment 2 case study working groups to present their preliminary findings. The Value of Treatment for Brain Disorders (VOT) is a health economics and outcomes research project coordinated by the European Brain Council (EBC). EBC conceptualized in 2015 the Value [...]

28 06-2021

EBC raises awareness on International Phenylketonuria Day

2021-06-28T07:41:17+00:0028-06-2021|News|

EBC is happy to recognise and support International Phenylketonuria (PKU) Day, which takes place annually on 28 June — the birthday of two stalwarts of PKU, Robert Guthrie (1916-1995) and Horst Bickel (1918-2000). The ongoing 2019-2021 Value of Treatment (VOT) project for Brain Disorders and its recent synthesis meeting on 8 June 2021 aimed to [...]

8 06-2021

Value of Treatment 2 Synthesis Meeting

2021-10-26T10:05:46+00:0008-06-2021|

  The European Brain Council (EBC) is pleased to invite you for the Value of Treatment 2 (VOT 2) Synthesis Meeting, to be held virtually on 8 June 2021 (13:00-17:00 CET). Experts participating in the research will present a synthesis of the results so far and examine the most critical issues in brain diseases in Europe from different perspectives including policymakers, innovators, academia [...]

27 05-2021

EBC launches “RETHINKING MS in times of COVID-19” on the occasion of World Multiple Sclerosis Day

2021-06-28T07:51:36+00:0027-05-2021|News|

On the occasion of the approaching World Multiple Sclerosis Day (30 May 2021), the European Brain Council is excited to announce the release of its new policy paper, "RETHINKING MS in times of COVID-19". This new paper is part of the main report "RETHINKING MS in Europe", a research-driven project offering tangible policy changes [...]

19 05-2021

IMI PARADIGM develops toolkit to make patient engagement in medicines development easier for all

2021-05-20T11:55:20+00:0019-05-2021|News|

There is consensus among stakeholders that patient engagement at different points of the medicines lifecycle is critical to fostering patient access to innovative therapeutic solutions, and delivering better health outcomes for patients.  IMI PARADIGM, a public private consortium consisting of patients, academia, industry, HTA bodies and regulators, developed a toolkit to make patient engagement [...]

Go to Top